June 2006

AstraZeneca Bets More Chips On China

Wednesday, June 28, 2006

AstraZeneca is investing $100 million more in China over the next three years to build the AstraZeneca Innovation Centre China, an R&D facility to study the benefits of new drugs to Chinese patients. Already one of the most heavily invested in China among big pharma companies, AstraZeneca is further distinguishing itself as the leader there with this new commitment.

[Read More]

ICON Steers Toward Integrated Oncology Service Model

Tuesday, June 27, 2006

During DIA 2006, CenterWatch got the inside scoop on ICON’s new The Oncology Solution service model during an interview with imaging CRO Beacon Bioscience’s David LaPoint, Vice President of Business Development. Beacon Biosciences was acquired by ICON Clinical in July 2004. According to LaPoint, the solution will allow ICON to bring together their full range of clinical service offerings, including imaging, central laboratory, IVRS and CRF data services.

[Read More]

CenterWatch’s 42nd Annual DIA Round Up

Monday, June 26, 2006

This year’s Drug Information Association (DIA) 42nd annual industry conference, held in Philadelphia, Penn attracted nearly 10,000 attendees from across every sector in the drug development industry. Presenting at the show were over 400 U.S. and close to 200 international companies, from both developed markets and emerging regions around the globe. Nearly 1,000 delegates from 50 countries were scheduled to attend.

[Read More]

Time To Embrace Paperless Clinical Trials

Wednesday, June 21, 2006

When it comes to efficient drug development, pharmaceutical companies have a lot to learn. Recent research we conducted at CenterWatch suggests, however, that they might just be getting t he message, at least when it comes to clinical trials In a recent survey, we polled users of electronic data capture (EDC) software – the folks on the front line of research who conduct their clinical trials using this software – for their views on the factors most likely to prevent future drug development delays.

[Read More]

Challenges in Communication

Wednesday, June 14, 2006

Recently, the well known industry chemist and blogger Derek Lowe, PhD discussed an important issue plaguing the drug development industry; a general lack of public knowledge with regard to how drugs are brought to market. Given the need for direct patient involvement in clinical trials, the issue is especially of great concern for our industry. The challenges and complexities of drug development are not easy tasks to relay to the layperson, but a greater attempt to bring public clarity to this process, would only benefit our shared goals: finding new therapies to treat disease…

[Read More]

NPR Interviews David DeMets on Drug Safety Monitoring Boards

Tuesday, June 13, 2006

In the wake of Vioxx and the recent events during the German biotech TeGenero AG’s trial, involving a severe immune reaction in six British subjects given an investigative monoclonal antibody, the industry has made a major effort to review trial safety precautions. Among other areas under scrutiny, the work of independent review boards (IRBs) has received much attention. Recently, the roles and challenges of Data Safety Monitoring Boards (DSMBs) have also been discussed in preventing further safety issues during clinical trials AND after market approval…

[Read More]